AAVantgarde Bio has announced the successful closing of a $141 million (€122 million) Series B financing round that was ...

Viridian seeks Priority Review for veligrotug, aiming for a potential mid-2026 commercial launch if approved. Global phase 3 trials for VRDN-003 in TED are underway, with a BLA submission planned by ...

Marguerite B. McDonald, MD, FACS, reflects on a first-year residency case that taught her the importance of trusting her ...

Deborah Ristvedt, DO, recalls a retinal detachment repair that took an unexpected turn, teaching lasting lessons in patient ...

The program begins with a discussion on the everyday challenges eye care professionals face in recognizing subtle signs of ...

James Chelnis, MD, FACS, is an ophthalmic plastic and reconstructive surgeon at Manhattan Face & Eye. At the 2025 American ...

To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had ...

The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies.

Specialists discuss diagnostic technologies, treatment strategies, and research that are improving outcomes for young ...

SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis ...

Second-generation anti-VEGF agents, like aflibercept 8 mg and faricimab, show improved efficacy and treatment durability in ...

The Phase 2 OptimUM-09 trial shows promising results for uveal melanoma, addressing the lack of approved systemic therapies.